etoposide + cisplatin + paclitaxel

EP + TP refers to a combination of two standard-of-care chemotherapy regimens used in the treatment of lung cancer: Etoposide plus Cisplatin (EP) and Paclitaxel plus Cisplatin (TP). These regimens are platinum-based combinations typically administered as first-line therapy for both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Etoposide functions as a topoisomerase II inhibitor, paclitaxel acts as a microtubule-stabilizing agent by binding to tubulin, and cisplatin serves as a DNA cross-linking agent. In clinical research, such as the Phase 2 trial NCT01737216 sponsored by Hebei Tumor Hospital, these regimens are used as the active comparator or backbone therapy to evaluate the additive effects of other agents like zoledronic acid in elderly lung cancer patients.

Other names

EP regimenTP regimenEtoposide/CisplatinPaclitaxel/CisplatinEP+TP